<DOC>
	<DOCNO>NCT00857675</DOCNO>
	<brief_summary>The purpose study determine whether Adefovir Dipivoxil effective safe treatment Chinese Patients HBeAg positive Chronic Hepatitis B 5 year .</brief_summary>
	<brief_title>A Efficacy Safety Study Adefovir Dipivoxil Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Aged 1865 year Presence HBsAg HBeAg time screen least 6 month prior screen . Positive HBV DNA plasma assay screen value equal 10 ( 6 ) copies/mL ( Roche COBAS AMPLICORTM HBV MONITOR Test , LLOD le 300 copies/mL ) time screen ( within 4 week randomisation ) . Evidence elevate serum ALT level define serum ALT level great equal 2.0 time ( inclusive ) upper limit normal range ( ULN ) previous 6 month , serum ALT level great 1.0 time ULN time screen . Evidence hepatocellular carcinoma ; Clinical sign liver decompensation ; Serum creatinine 1.5 mg/dL ; ALT 10 x ULN ; seropositivity hepatitis C D virus HIV ; Lamivudine therapy within 3 month prior screen ; ADV therapy antiHBV therapy within previous 6 month ; Use systemic antiviral agent , immunomodulators , immunosuppressive therapy , Chinese Traditional Medicines agent know low ALT level study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>HBV DNA suppression</keyword>
	<keyword>ALT normalisation</keyword>
	<keyword>Viral resistance</keyword>
	<keyword>HBeAg seroconversion</keyword>
</DOC>